drugset / Trial / NCT01884285
AZD8186 First Time In Patient Ascending Dose Study
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a phase I, open-label, multicentre study of AZD8186 administered orally in patients with advanced castrate-resistant prostate cancer (CRPC), squamous non-small cell lung cancer (sqNSCLC), triple negative breast cancer (TNBC) and known PTEN-deficient/mutated or PIK3CB mutated/amplified advanced solid malignancies as monotherapy and in combination with abiraterone acetate or AZD2014.
Timeline
- Start
- 2013-07-09
- Primary completion
- 2019-03-31
- Completion
- 2020-02-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD8186 | Small molecule | — | Oral |
| Subject | Vistusertib | Small molecule | — | — |
| Background | Abiraterone acetate | Small molecule | — | — |
| Background | Prednisone | Other / unclassified | — | — |